On 21 March 2024, the company released the great news about the peer-reviewed publication in the journal Science Translational Medicine of data-sets that demonstrate the ability of CIC-1 inhibition to restore muscle function in patients suffering from myasthenia gravis (MG) and in animal models of MG.
And today, 22 March 2024, NMD Pharma A/S releases even more fantastic news as the company has received FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US.
Read the full press releases here: https://www.nmdpharma.com/press-releases